WALTHAM, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced ...
Session Date and Time: Monday, April 28, 2:00 - 5:00 p.m.
Triple-negative breast cancer, an aggressive type of breast cancer, accounts for 10% of all breast cancer cases in the United ...
Good morning and welcome to PDS Biotech's 4th quarter in full year 2024 earnings conference call. Thank you, operator. Good morning, everyone, and welcome to PDS Biotech's 2024 results and clinical ...
AZoLifeSciences on MSN11h
Study Sheds Light on Cell’s Adaptive Response to StressThe body's cells respond to stress-toxins, mutations, starvation or other assaults-by pausing normal functions to focus on ...
Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ETCompany ParticipantsBruce Mackle - LifeSci Advisors, ...
Durable complete response (CR) in a MCC patient treated with 15 mg/kg solnerstotug + cemiplimab. Patient continues on ...
A new study published in Science by a team of scientists across five continents led by King Abdullah University of Science ...
FAMU-FSU College of Engineering researchers have created a new method for studying protein degradation within immune cells ...
Researchers from the La Jolla Institute for Immunology recently used the Expanse supercomputer at the San Diego Supercomputer ...
Rutgers Health researchers have discovered that networks of misplaced immune cells drive an aggressive lung disease, ...
Treatment with CAN-2409, an off-the-shelf immunotherapy, elicited responses among patients with pretreated stage 3/4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback